HUTCHMED
First ATTC deal: GSK $110m upfront for KRAS/EGFRHUTCHMED
SAFFRON data positions savo combo competitivelyHUTCHMED
H126: China recovery and Fruzaqla drive sales growthHUTCHMED
ATTC data confirms clinical potentialHUTCHMED
Momentum in revenues, ATTC development promiseHUTCHMED
A month of notable pipeline progressHUTCHMED
Pipeline potential underpins long-term growth prospectsHUTCHMED
ESMO: fruquintinib’s significant benefit in kidney cancerHUTCHMED
H125: Growth prospects remain intactHUTCHMED
Orpathys/Tagrisso combination approved in China